Clinical Trials Browser

Phase 1 × Terminated × 130-nm albumin-bound paclitaxel × Clear all

NCT06528093 2026-02-03

A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

Phase 1 Terminated

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT06199466 2025-12-08

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT02047500 2025-05-11

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Phase 1 Terminated

19 enrolled 6 charts

Gastrointestinal

Pancreatic Neoplasms

NCT05267470 2025-03-25

FORTITUDE-201

Phase 1 Terminated

74 enrolled 22 charts

Squamous-Cell Non-Small-Cell Lung Cancer

NCT03520790 2025-03-21

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT05911308 2025-03-21

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02672917 2025-01-28

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT03435250 2024-07-25

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Phase 1 Terminated

Lymphoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04046887 2024-01-05

Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT03928314 2023-12-15

Study of ORIC-101 in Combination With Anticancer Therapy

Phase 1 Terminated

Other solid neoplasm

Solid Tumor

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT02608229 2021-04-21

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase 1 Terminated

18 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02267707 2019-11-01

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Phase 1 Terminated

Gastrointestinal

Cholestasis, Pancreatic Neoplasms

NCT02707328 2019-07-30

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT01822756 2018-02-12

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

Phase 1 Terminated

42 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01929941 2018-01-17

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Phase 1 Terminated

BreastGastrointestinalLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Pancreatic Neoplasms

NCT02651727 2017-07-27

Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT02317419 2016-07-26

A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors

Phase 1 Terminated

Neoplasms